{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:06:29Z","timestamp":1789545989189,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["517063424"],"award-info":[{"award-number":["517063424"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bonr.2026.101933","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:34:06Z","timestamp":1781886846000},"page":"101933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Individualized antiresorptive therapy in fibrous dysplasia and McCune-Albright syndrome: A retrospective cohort study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7722-2068","authenticated-orcid":false,"given":"Tonio","family":"Lipkow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-6021","authenticated-orcid":false,"given":"Mikolaj","family":"Bartosik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1404-378X","authenticated-orcid":false,"given":"Johann","family":"Sprick-Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0200-8431","authenticated-orcid":false,"given":"Florian","family":"Barvencik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2382-8348","authenticated-orcid":false,"given":"Michael","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-5013","authenticated-orcid":false,"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2026.101933_bb0005","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s11154-023-09832-2","article-title":"Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis","volume":"24","author":"Bertin","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bonr.2026.101933_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of g\u03b1s activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bonr.2026.101933_bb0015","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101933_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115784","article-title":"Bisphosphonates for the treatment of fibrous dysplasia of bone","volume":"143","author":"Chapurlat","year":"2021","journal-title":"Bone"},{"issue":"Suppl. 1","key":"10.1016\/j.bonr.2026.101933_bb0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","article-title":"Pathophysiology and medical treatment of pain in fibrous dysplasia of bone","volume":"7","author":"Chapurlat","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bonr.2026.101933_bb0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1359\/JBMR.041111","article-title":"An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone","volume":"20","author":"Collins","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bonr.2026.101933_bb0035","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1750-1172-7-S1-S4","article-title":"McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia","volume":"7","author":"Collins","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bonr.2026.101933_bb0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"de Castro","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101933_bb0045","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101933_bb0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101933_bb0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bonr.2026.101933_bb0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101933_bb0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00198-013-2585-1","article-title":"Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases","volume":"25","author":"Ganda","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2026.101933_bb0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/clinem\/dgad589","article-title":"Phenotyping pain in patients with fibrous dysplasia\/McCune-Albright syndrome","volume":"109","author":"Golden","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101933_bb0075","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101933_bb0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bonr.2026.101933_bb0085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jbmr.2999","article-title":"Outcome of long-term bisphosphonate therapy in McCune-Albright syndrome and polyostotic fibrous dysplasia","volume":"32","author":"Majoor","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101933_bb0090","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101933_bb0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/17453674.2019.1608117","article-title":"Pain in fibrous dysplasia: relationship with anatomical and clinical features","volume":"90","author":"Majoor","year":"2019","journal-title":"Acta Orthop."},{"key":"10.1016\/j.bonr.2026.101933_bb0100","first-page":"981","article-title":"Cellular and molecular basis of fibrous dysplasia","volume":"16","author":"Marie","year":"2001","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.bonr.2026.101933_bb0105","first-page":"1059","article-title":"Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia","volume":"150","author":"Marie","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bonr.2026.101933_bb0110","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101933_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116744","article-title":"Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia\/McCune-Albright syndrome","volume":"171","author":"Meier","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2026.101933_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00223-025-01379-5","article-title":"Developing a standardised dataset for natural history studies in fibrous dysplasia\/McCune-Albright syndrome","volume":"116","author":"Priego Zurita","year":"2025","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bonr.2026.101933_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227279","article-title":"Changes in gene expression in human skeletal stem cells transduced with constitutively active Gs\u03b1 correlates with hallmark histopathological changes seen in fibrous dysplastic bone","volume":"15","author":"Raimondo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bonr.2026.101933_bb0130","first-page":"1587","article-title":"Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation","volume":"151","author":"Riminucci","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bonr.2026.101933_bb0135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S8756-3282(03)00064-4","article-title":"Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression","volume":"33","author":"Riminucci","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2026.101933_bb0140","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1073\/pnas.89.11.5152","article-title":"Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome","volume":"89","author":"Schwindinger","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bonr.2026.101933_bb0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","article-title":"Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption","volume":"34","author":"S\u00f8lling","year":"2023","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2026.101933_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.582316","article-title":"Response to zoledronic acid infusion in children with fibrous dysplasia","volume":"8","author":"Tripathy","year":"2020","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.bonr.2026.101933_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116819","article-title":"Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study","volume":"174","author":"Trojani","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2026.101933_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032550","article-title":"Pharmacological interventions targeting pain in fibrous dysplasia\/McCune-Albright syndrome","volume":"24","author":"Tucker-Bartley","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bonr.2026.101933_bb0165","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2026.101933_bb0170","first-page":"247","article-title":"Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience","volume":"66","author":"Valadares","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101933_bb0175","doi-asserted-by":"crossref","first-page":"e2980","DOI":"10.1210\/clinem\/dgab212","article-title":"Denosumab reduces lesional fluoride skeletal burden on Na[18F]F PET-CT in patients with fibrous dysplasia\/McCune-Albright syndrome","volume":"106","author":"van der Bruggen","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101933_bb0180","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101933_bb0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4158\/EP-2018-0328","article-title":"Efficacy and safety of bisphosphonate therapy in McCune-Albright syndrome-related polyostotic fibrous dysplasia: a single-center experience","volume":"25","author":"Wang","year":"2019","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bonr.2026.101933_bb0190","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2026.101933_bb0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI118773","article-title":"Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome","volume":"98","author":"Yamamoto","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bonr.2026.101933_bb0200","first-page":"E428","article-title":"Expression of an active G\u03b1(s) mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance","volume":"115","author":"Zhao","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:40:13Z","timestamp":1789544413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187226000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S2352187226000379"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101933","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized antiresorptive therapy in fibrous dysplasia and McCune-Albright syndrome: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101933"}}